Alio WEAR Study: Long-term Wear of the Alio Platform

计划入组 250 人 · 首次发布于 2023 年 9 月 28 日

ECM and Monitoring w/ Alio Smart Patch in Cancer Pts Receiving Chemotherapy

计划入组 35 人 · 首次发布于 2024 年 10 月 24 日

The Jordan Study for End-Stage Renal Disease Subjects

计划入组 75 人 · 首次发布于 2022 年 5 月 19 日

Oncoferon(Alios BioPharma, Inc.)

4-azidocytidine analogs (Alios BioPharma/Centers for Disease Control and Prevention)

AL-516

Alio, Inc.

United States

Alios BioPharma, Inc.

United States

ALTO NEUROSCIENCE, INC.

United States

Alio Launches CAVA Study to Expand Wearable Platform for Chronic Condition Monitoring

Alto Neuroscience's ALTO-300 Shows Promise in Phase 2b Trial for Major Depressive Disorder

Alto Neuroscience Faces Class Action Lawsuit Following ALTO-100 Phase 2b Trial Failure